Carotid Flow Time Measurement Guided Fluid Management During Spinal Anesthesia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-07-31

Study Completion Date

2022-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Fluid management is a fundamental aspect of anesthesia. Several monitorization methods have been introduced to optimize fuid management.

To date neither of them were ideal. Corrected flow time measurement (FTc) in the carotid artery was recently introduced to detect fluid responsiveness.

Spinal anesthesia causes hypotension and fluid preloading is suggested to overcome this problem.

The aim of this study is to evaluate the effect of FTc guided fluid loading on spinal anesthesia induced hypotension.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Fluid Responsiveness Through the Corrected Carotid Flow Time, Before and After Sternotomy

NCT06967142

Coronary Artery Disease

COMPLETED

Hemodynamic Response During Goal Directed Fluid Therapy in the OR

NCT02365688

Hemodynamic Instability

TERMINATED NA

Fluid Responsiveness With Passive Leg Raising in Patients Undergoing Coronary Artery Bypass Surgery

NCT07245485

Fluid Responsiveness Passive Leg Raising Corrected Carotid Flow Time

ACTIVE_NOT_RECRUITING

The Stroke Volume Optimization of Goal Directed Fluid Therapy During Radical Cystectomy

NCT03262480

Radical Cystectomy

COMPLETED NA

Cardiac Output and Duplex Sonography in Carotid Endarterectomy

NCT02230358

Carotid Stenosis

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients will be randomly allocated into 3 groups. Group C (Control) will receive spinal anesthesia after initiation of intravenous (iv) access without fluid preloading and will receive 2 ml/kg Ringer's lactate during anesthesia..

Group P (preloading) will receive 10 ml/kg Ringer's lactate before spinal block.

In Group FTc, ultrasonographic measurement of corrected flow time in carotid artery will be measured using 10-5 megahertz linear probe. On the two-dimensional image, the optimal image of the long-axis view will be obtained at the left common carotid artery. The sample volume will be placed on the center of the lumen, 2 cm proximal to the bulb, and a pulsed wave Doppler examination will be performed. Cardiac cycle time and carotid flow time will be measured. Carotid flow time will be measured between the upstroke of the flow tracing and the dicrotic notch, and it will be corrected for pulse rate by dividing flow time by the square root of the cardiac cycle time to calculate corrected carotid artery flow time (flow time/√cycle time).

The blood pressure will be measured 5 minutes before spinal anesthesia is commenced (baseline) and every minute afterwards until end of surgery.

Group FTc will receive a 500 mL Ringer's lactate bolus if the FTc is \<349 ms (fluid responder); the FTc measurement will be repeated 15 minutes later and additional 500 mL Ringer's lactate bolus will be applied if the patient is still considered fluid responder; this sequence will be repeated until the patient's FTc is \> 349 ms (non responder).

Ephedrine bolus will be used in allh groups if the mean arterial pressure drops below 30% of the baseline value.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Meniscus Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Prospective randomised

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group Control

will receive 2 ml/kg "Ringer's lactate" Lafleks® during anesthesia

Group Type ACTIVE_COMPARATOR

Group Control 2 ml/kg "Ringer's lactate" Lafleks®

Intervention Type OTHER

will receive 2 ml/kg "Ringer's lactate" Lafleks® during anesthesia

Group Preloading

will receive 10 ml/kg "Ringer's lactate" Lafleks® fluid preloading

Group Type EXPERIMENTAL

Group Preloading 10 ml/kg "Ringer's lactate" Lafleks®

Intervention Type OTHER

will receive 10 ml/kg "Ringer's lactate" Lafleks® fluid preloading

Group Carotis FTc

will receive 500 ml "Ringer's lactate" Lafleks® if the patient is fluid responder

Group Type EXPERIMENTAL

Group Carotis FTc 500 ml "Ringer's lactate" Lafleks®

Intervention Type OTHER

will receive 500 ml "Ringer's lactate" Lafleks® if the patient is fluid responder

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Group Carotis FTc 500 ml "Ringer's lactate" Lafleks®

will receive 500 ml "Ringer's lactate" Lafleks® if the patient is fluid responder

Intervention Type OTHER

Group Preloading 10 ml/kg "Ringer's lactate" Lafleks®

will receive 10 ml/kg "Ringer's lactate" Lafleks® fluid preloading

Intervention Type OTHER

Group Control 2 ml/kg "Ringer's lactate" Lafleks®

will receive 2 ml/kg "Ringer's lactate" Lafleks® during anesthesia

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult patients (19-80 years of age) who were scheduled to undergo arthroscopic knee surgery under spinal anesthesia

Exclusion Criteria

* Mean blood pressure \< 70 mmHg before induction of general anesthesia
* Patients who have currently taken angiotensin-converting enzyme inhibitor
* Patients who have currently taken angiotensin receptor blocker
* the presence of carotid artery stenosis \> 50%
* cardiac rhythm other than sinus
* unstable angina
* a left ventricular ejection fraction of \< 40%
* severe vascular disease
* implanted pacemaker/cardioverter
* autonomic nervous system disorders
* pregnancy

Minimum Eligible Age

19 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No